PapersFlow Research Brief
Cancer-related Molecular Pathways
Research Guide
What is Cancer-related Molecular Pathways?
Cancer-related molecular pathways are intracellular signaling networks, such as the p53 signaling pathway, that regulate cell cycle control, apoptosis, and tumor suppression, with disruptions like p53 mutations driving cancer development.
This field centers on the p53 signaling network and its roles in cell cycle regulation, tumor suppression, apoptosis induction, and cancer therapy responses. Over 84,000 papers explore p53-MDM2 interactions, cyclin-dependent kinases, and p53 regulation mechanisms in cancer. Key works include highly cited reviews on p53 functions and broader cancer hallmarks.
Topic Hierarchy
Research Sub-Topics
p53-MDM2 Interaction
This sub-topic investigates the regulatory feedback loop between p53 and MDM2 proteins in tumor suppression. Researchers study ubiquitination mechanisms, inhibitors, and dysregulation in cancers.
p53 in Apoptosis
This sub-topic examines p53-mediated transcriptional activation of pro-apoptotic genes like PUMA and BAX. Researchers analyze pathway cross-talk, mitochondrial regulation, and therapeutic modulation.
p53 Cell Cycle Regulation
This sub-topic covers p53 activation of p21 and CDK inhibitors to enforce G1 arrest. Researchers explore DNA damage responses, checkpoint control, and cyclin interactions.
p53 Mutations in Cancer
This sub-topic analyzes dominant-negative and gain-of-function effects of p53 hotspot mutations. Researchers classify mutation spectra, prognostic impacts, and tissue-specific patterns.
p53 Tumor Suppressor Network
This sub-topic maps p53's extensive interactome and signaling network in stress responses. Researchers use systems biology to model pathway dynamics and therapeutic vulnerabilities.
Why It Matters
Disrupted p53 pathways contribute to uncontrolled cell proliferation in most human cancers, as p53 mutations occur commonly across tumor types including colon, lung, and breast (Hollstein et al., 1991, 'p53 Mutations in Human Cancers'). This informs targeted therapies, such as those modulating p53-MDM2 interactions for restoring tumor suppression. Wafik S. El-Deiry et al. (1993) identified WAF1 as a p53-mediated cell cycle inhibitor, enabling strategies to reactivate p53 functions in over 50% of cancers with p53 defects. Insights from Douglas Hanahan and Robert A. Weinberg (2011, 'Hallmarks of Cancer: The Next Generation') link these pathways to sustaining proliferative signaling and resisting cell death, guiding precision oncology.
Reading Guide
Where to Start
'p53, the Cellular Gatekeeper for Growth and Division' by Arnold J. Levine (1997), as it provides a foundational overview of p53's core functions in growth control and division, accessible before diving into networks or mutations.
Key Papers Explained
Douglas Hanahan and Robert A. Weinberg's 'The Hallmarks of Cancer' (2000) establishes broad cancer capabilities, expanded in their 'Hallmarks of Cancer: The Next Generation' (2011) with pathway details like apoptosis resistance. Arnold J. Levine's 'p53, the Cellular Gatekeeper for Growth and Division' (1997) focuses on p53 mechanisms, while Bert Vogelstein et al.'s 'Surfing the p53 network' (2000) maps p53 interactions building on Levine. Hollstein et al. (1991, 'p53 Mutations in Human Cancers') and El-Deiry et al. (1993, 'WAF1, a potential mediator of p53 tumor suppression') provide mutation data and downstream effectors linking to hallmarks.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research extends p53 network analysis to ubiquitin-mediated regulation (Hershko and Ciechanover, 1998) and stem cell contexts (Reya et al., 2001), with preprints absent but emphasis on late recurrence factors in breast cancer (Nishimura et al., 2013).
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Hallmarks of Cancer: The Next Generation | 2011 | Cell | 64.9K | ✓ |
| 2 | The Hallmarks of Cancer | 2000 | Cell | 28.3K | ✓ |
| 3 | Apoptosis: A Basic Biological Phenomenon with Wideranging Impl... | 1972 | British Journal of Cancer | 15.5K | ✓ |
| 4 | Evaluation of Factors Related to Late Recurrence - Later than ... | 2013 | Oncology | 13.2K | ✓ |
| 5 | Stem cells, cancer, and cancer stem cells | 2001 | Nature | 9.6K | ✓ |
| 6 | THE UBIQUITIN SYSTEM | 1998 | Annual Review of Bioch... | 8.7K | ✕ |
| 7 | WAF1, a potential mediator of p53 tumor suppression | 1993 | Cell | 8.4K | ✕ |
| 8 | p53 Mutations in Human Cancers | 1991 | Science | 8.1K | ✕ |
| 9 | p53, the Cellular Gatekeeper for Growth and Division | 1997 | Cell | 7.7K | ✓ |
| 10 | Surfing the p53 network | 2000 | Nature | 6.6K | ✕ |
Frequently Asked Questions
What role does p53 play in tumor suppression?
p53 acts as a cellular gatekeeper that halts cell growth and division in response to DNA damage. Arnold J. Levine (1997, 'p53, the Cellular Gatekeeper for Growth and Division') describes p53 inducing cell cycle arrest or apoptosis to prevent tumor formation. This function is lost in many cancers due to mutations.
How do p53 mutations differ across cancer types?
p53 mutations cluster in evolutionarily conserved codons and vary by cancer type, such as colon, lung, and breast. Hollstein et al. (1991, 'p53 Mutations in Human Cancers') analyzed spectra showing distinct patterns in reticuloendothelial and hemopoietic tissues. These differences reflect tissue-specific selective pressures.
What is the p53-MDM2 interaction?
MDM2 negatively regulates p53 by promoting its ubiquitination and degradation via the ubiquitin system. Avram Hershko and Aaron Ciechanover (1998, 'THE UBIQUITIN SYSTEM') detail how ubiquitin ligation targets regulatory proteins like p53 for breakdown. Bert Vogelstein et al. (2000, 'Surfing the p53 network') map this as a core feedback loop in the p53 network.
How does p53 mediate cell cycle arrest?
p53 induces WAF1 (p21) expression to inhibit cyclin-dependent kinases and block cell cycle progression. Wafik S. El-Deiry et al. (1993, 'WAF1, a potential mediator of p53 tumor suppression') identified WAF1 as a downstream effector of p53 tumor suppression. This mechanism prevents propagation of damaged DNA.
What are the hallmarks of cancer involving molecular pathways?
Cancer hallmarks include sustaining proliferative signals, evading growth suppressors, and resisting cell death, often via pathway dysregulation. Douglas Hanahan and Robert A. Weinberg (2000, 'The Hallmarks of Cancer') outlined six core capabilities. Their 2011 update ('Hallmarks of Cancer: The Next Generation') added reprogramming metabolism and immune evasion.
What is the connection between p53 and apoptosis?
p53 triggers apoptosis to eliminate potentially cancerous cells. J. F. R. Kerr et al. (1972, 'Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics') defined apoptosis as ordered cell death. p53 integrates this process in response to oncogenic stress.
Open Research Questions
- ? How can p53-MDM2 inhibitors selectively restore p53 function in tumors without affecting normal cells?
- ? What are the tissue-specific consequences of distinct p53 mutation spectra?
- ? How does the ubiquitin system fine-tune p53 levels under varying stress conditions?
- ? In what ways do cancer stem cells evade p53-mediated tumor suppression?
- ? How do late-recurring breast cancers alter p53 pathway dynamics beyond 10 years post-treatment?
Recent Trends
The field encompasses 84,259 works on p53 signaling, with sustained high citations for foundational papers like Hanahan and Weinberg (2011, 64,861 citations) and Hollstein et al. (1991, 8,083 citations), but no growth rate or recent preprints/news available.
Research Cancer-related Molecular Pathways with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cancer-related Molecular Pathways with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers